These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

303 related articles for article (PubMed ID: 16121697)

  • 1. Gene therapy with poxvirus vectors.
    Moroziewicz D; Kaufman HL
    Curr Opin Mol Ther; 2005 Aug; 7(4):317-25. PubMed ID: 16121697
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prospects and limitations of recombinant poxviruses for prostate cancer immunotherapy.
    Hwang C; Sanda MG
    Curr Opin Mol Ther; 1999 Aug; 1(4):471-9. PubMed ID: 11713762
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Poxviruses as vectors for cancer immunotherapy.
    Kwak H; Hörig H; Kaufman HL
    Curr Opin Drug Discov Devel; 2003 Mar; 6(2):161-8. PubMed ID: 12669450
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Virotherapy clinical trials for regional disease: in situ immune modulation using recombinant poxvirus vectors.
    Mastrangelo MJ; Lattime EC
    Cancer Gene Ther; 2002 Dec; 9(12):1013-21. PubMed ID: 12522440
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pox viruses as eukaryotic cloning and expression vectors: future medical and veterinary vaccines.
    Taylor J; Paoletti E
    Prog Vet Microbiol Immunol; 1988; 4():197-217. PubMed ID: 3078866
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Poxvirus vaccines for cancer and HIV therapy.
    Essajee S; Kaufman HL
    Expert Opin Biol Ther; 2004 Apr; 4(4):575-88. PubMed ID: 15102606
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Poxvirus-based vectors as vaccine candidates.
    Tartaglia J; Pincus S; Paoletti E
    Crit Rev Immunol; 1990; 10(1):13-30. PubMed ID: 2407263
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pox viral vaccine approaches.
    Arlen PM; Kaufman HL; DiPaola RS
    Semin Oncol; 2005 Dec; 32(6):549-55. PubMed ID: 16338420
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The potential role of fowlpox virus in rational vaccine design.
    Beukema EL; Brown MP; Hayball JD
    Expert Rev Vaccines; 2006 Aug; 5(4):565-77. PubMed ID: 16989636
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Head-to-head comparison on the immunogenicity of two HIV/AIDS vaccine candidates based on the attenuated poxvirus strains MVA and NYVAC co-expressing in a single locus the HIV-1BX08 gp120 and HIV-1(IIIB) Gag-Pol-Nef proteins of clade B.
    Gómez CE; Nájera JL; Jiménez EP; Jiménez V; Wagner R; Graf M; Frachette MJ; Liljeström P; Pantaleo G; Esteban M
    Vaccine; 2007 Apr; 25(15):2863-85. PubMed ID: 17113200
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Viral vectors for gene transfer into antigen presenting cells.
    Monahan SJ; Salgaller ML
    Curr Opin Mol Ther; 1999 Oct; 1(5):558-64. PubMed ID: 11249662
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biology and application of alphaviruses in gene therapy.
    Lundstrom K
    Gene Ther; 2005 Oct; 12 Suppl 1():S92-7. PubMed ID: 16231060
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improving recombinant MVA immune responses: potentiation of the immune responses to HIV-1 with MVA and DNA vectors expressing Env and the cytokines IL-12 and IFN-gamma.
    Abaitua F; Rodríguez JR; Garzón A; Rodríguez D; Esteban M
    Virus Res; 2006 Mar; 116(1-2):11-20. PubMed ID: 16214252
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Engineered adenovirus serotypes for overcoming anti-vector immunity.
    Dharmapuri S; Peruzzi D; Aurisicchio L
    Expert Opin Biol Ther; 2009 Oct; 9(10):1279-87. PubMed ID: 19645630
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Introduction to viral vectors.
    Warnock JN; Daigre C; Al-Rubeai M
    Methods Mol Biol; 2011; 737():1-25. PubMed ID: 21590391
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Poxviruses as vaccine vectors.
    Pastoret PP; Vanderplasschen A
    Comp Immunol Microbiol Infect Dis; 2003 Oct; 26(5-6):343-55. PubMed ID: 12818621
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Innate immune response induced by gene delivery vectors.
    Sakurai H; Kawabata K; Sakurai F; Nakagawa S; Mizuguchi H
    Int J Pharm; 2008 Apr; 354(1-2):9-15. PubMed ID: 17640834
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multimeric soluble CD40 ligand (sCD40L) efficiently enhances HIV specific cellular immune responses during DNA prime and boost with attenuated poxvirus vectors MVA and NYVAC expressing HIV antigens.
    Gómez CE; Nájera JL; Sánchez R; Jiménez V; Esteban M
    Vaccine; 2009 May; 27(24):3165-74. PubMed ID: 19446187
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Technical knockout: understanding poxvirus pathogenesis by selectively deleting viral immunomodulatory genes.
    Johnston JB; McFadden G
    Cell Microbiol; 2004 Aug; 6(8):695-705. PubMed ID: 15236637
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Challenges and strategies: the immune responses in gene therapy.
    Zhou HS; Liu DP; Liang CC
    Med Res Rev; 2004 Nov; 24(6):748-61. PubMed ID: 15250039
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.